Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2Neuroendocrine Tumors 1Neoplasm Metastasis 1Liver Malignancy 1Cholangiocarcinoma 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 11Cisplatin 10pembrolizumab 5Oxaliplatin 4durvalumab 3Magnetic Resonance Spectroscopy 3Leucovorin 3Fluorouracil 3tivozanib 2Specimen Handling 2Capecitabine 2zimberelimab 1trametinib 1tislelizumab 1quemliclustat 1pertuzumab 1olaparib 1irinotecan sucrosofate 1atezolizumab 1anlotinib 1Yttrium-90 1Tissue Adhesives 1Tegafur 1Stents 1S 1 (combination) 1Ritonavir 1Radiosurgery 1Pancreaticojejunostomy 1Pancreaticoduodenectomy 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × Yttrium-90 × 1 year × Clear all
NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Beth Israel Deaconess Medical Center

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡